CN1214784C - Quick-releasing talbet in vagina and its preparing method - Google Patents
Quick-releasing talbet in vagina and its preparing method Download PDFInfo
- Publication number
- CN1214784C CN1214784C CN 03130267 CN03130267A CN1214784C CN 1214784 C CN1214784 C CN 1214784C CN 03130267 CN03130267 CN 03130267 CN 03130267 A CN03130267 A CN 03130267A CN 1214784 C CN1214784 C CN 1214784C
- Authority
- CN
- China
- Prior art keywords
- tablet
- vagina
- active components
- vaginas
- release tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001215 vagina Anatomy 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 239000000945 filler Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000853 adhesive Substances 0.000 claims abstract description 5
- 229940088597 hormone Drugs 0.000 claims abstract description 4
- 239000005556 hormone Substances 0.000 claims abstract description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims abstract description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 3
- 230000001857 anti-mycotic effect Effects 0.000 claims abstract description 3
- 239000002543 antimycotic Substances 0.000 claims abstract description 3
- 230000023597 hemostasis Effects 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 44
- 239000007948 fast release tablet Substances 0.000 claims description 38
- 239000003826 tablet Substances 0.000 claims description 36
- 239000008187 granular material Substances 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 8
- 238000007907 direct compression Methods 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229960003376 levofloxacin Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 7
- 229960005249 misoprostol Drugs 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229960004099 azithromycin Drugs 0.000 claims description 5
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- -1 antiviral class Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 239000008118 PEG 6000 Substances 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 238000005092 sublimation method Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 4
- 210000003756 cervix mucus Anatomy 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 229940127293 prostanoid Drugs 0.000 abstract 1
- 150000003814 prostanoids Chemical class 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 241000331528 Chlorophytum capense Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a quick-releasing tablet in vaginas and a preparation method. The quick-releasing tablet in vaginas comprises active components of medicines: antibiotic type active components, antimycotic type active components, antivirus type active components, hormone type active components, prostanoid active components, family-planning type active components, hemostasis type active components, antipyretic and antalgesic type active components, dysmenorrhea prevention type active components, or other medicine active components which are suitable for the medication in vaginas. The applicable auxiliary materials for pharmacy comprise filling agents, adhesive agents and disintegrating agents, and the filling agents comprise water-soluble filling agents and water insoluble filling agents. The present invention has the advantages that after the quick-releasing tablet in vaginas contact vaginal secretions, the quick-releasing tablet in vaginas can quickly disintegrate, disperse or dissolve; the quick-releasing tablet in vaginas is absorbed by vaginal mucous membranes to have local treatment action; after the quick-releasing tablet in vaginas enters systemic circulation; the quick-releasing tablet in vaginas has systemic treating action; the application is convenient without special auxiliary appliances; uncomfortableness is little; the medicine does not spill out of vaginas, the medication is correct, and the compliance of patients is favorable. The preparation method is easy and practical, and the preparing cost is low.
Description
Technical field
The present invention relates to a kind of vagina immediate release drug dosage form, particularly relate to a kind of vagina fast-release tablet and preparation method thereof.
Background technology
In order to reach prevention and treatment disease purpose, except that gastrointestinal administration commonly used, also have many other administration routes and method, as mucosa delivery, promptly by oral cavity, nasal cavity, eye, rectum, skin, vaginal mucosa administration.Abundant blood capillary is arranged under the mucosa at these positions, medicine is imposed on the mucosa, can directly enter the body circulation through absorbing, and without gastral physiological environment, can avoid the first pass effect of liver, be very suitable for to GI irritation greatly, easily destroyed and, have the characteristics fast, that dosage is little, blood drug level is steady, bioavailability is high and side effect is low that absorb easily by the use of the medicine of liver metabolism by gastric acid and digestive enzyme, therefore come into one's own day by day.
The physiological environment of vagina and gastrointestinal tract, position, oral cavity are different, and vagina position fluid flow is less, and a little less than the wriggling intensity rhythm, pH value is at 3.8-4.7, and the vagina PH value of infection is between 5.5-7.0.According to the physiological condition of vagina, vagina administration has tablet, capsule, vagina effervescence, vagina and sticks sheet, pessary, rod, bolt, ointment, frost, liquor, membrane, sponginum etc.For example, following patent documentation WO9603135, CN1057004, WO9507071, CN1242193, CN1245059 and US6006909 just disclose a kind of pharmaceutical dosage form and manufacture method thereof of vagina administration respectively.
The pharmaceutical dosage form of the disclosed vagina administration of above-mentioned patent documentation has the different characteristics and the scope of application, but also respectively there are some shortcomings, mainly be: stick sheet and capsule etc. as the solid dosage forms of vagina administration, general vagina tablet, vagina, because of its disintegration rate slow, particularly under the less situation of intravaginal juice, the disintegrate rate of dispersion is more slow, has influenced drug release; The rate of release of membrane, sponginum medicine is then more slow; Though vagina effervescence can disperse in the very fast disintegrate of intravaginal, but owing to contain effervescent composition (carbonate and organic acid) in the component, the general tablet complexity of its preparation technology many, and need under being lower than 30% environment, relative humidity prepare, therefore very high to technology and preparation environmental requirement, and product should not be preserved; Powder, granule should use very inconvenient; What vagina administration was commonly used then exists release slow for suppository (or medicine plug), may overflow extravaginal problem again after the intravaginal fusion, not only pollutes, and dosage also is difficult for grasping; And vagina also flows out outside the vagina easily with semi-solid preparation such as ointment, cream, gel and liquid preparation such as solution, drop, and dosage is difficult for grasping; Pessary, stick be then more to be used to practise contraception and the slow release of hormone, is not suitable for the medicine that need bring into play curative effect as early as possible.
Summary of the invention
Technical problem to be solved by this invention is, overcomes the shortcoming of the pharmaceutical dosage form of the disclosed vagina administration of above-mentioned patent documentation, vagina fast-release tablet that provide a kind of and conveniently use, dose is easy to grasp, can not pollute and rate of release is fast and preparation method thereof.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is: vagina fast-release tablet of the present invention comprises: the adjuvant that active constituents of medicine and pharmacy are suitable for; Described active constituents of medicine comprises: antibiotics, antimycotic, antiviral class, hormones, prostaglandins, family planning class, hemostasis class, antipyretic analgesic class, anti-dysmenorrhea class or other are applicable to the active constituents of medicine of intravaginal medication; The adjuvant that described pharmacy is suitable for comprises: filler, binding agent and disintegrating agent; Described filler comprises water-soluble filler and water-insoluble filler, and the two weight ratio is 10: 0.5-0.5: 10, and preferred weight ratio is 8: 1-1: 8, the two total consumption is the heavy 15-75% of sheet, preferable amount is the heavy 30-65% of sheet; When adopting direct compression process to prepare tablet, described adhesive consumption is the heavy 0.5-20% of sheet, and preferable amount is the heavy 2.0-10% of sheet, when adopting lyophilization to prepare tablet, described adhesive consumption is the heavy 1.0-40% of sheet, and preferable amount is the heavy 2.0-20% of sheet; The consumption of described disintegrating agent is the heavy 0.5-20% of sheet, and preferable amount is the heavy 1.0-10% of sheet.
Described water-soluble filler is selected from sucrose, lactose, glucose, maltose or other water-soluble sugars, mannitol, sorbitol, xylitol, erithritol or other water solublity sugar alcohols, glycine, lysine, proline or other water-soluble amino acid, taurine; Described water-insoluble filler comprises: starch based and cellulose family filler; Described starch based is selected from the starch that starch, pregelatinized Starch or other pharmacy are suitable for; Described cellulose family is selected from the filler that the suitable water-insoluble of microcrystalline Cellulose, ethyl cellulose, low-substituted hydroxypropyl cellulose or other pharmacy has disintegrating property concurrently.
The fine polymer powder that the particle diameter that when adopting direct compression process to prepare tablet, described binding agent is selected from syrup, gelatinized corn starch, CMC-Na solution, PVP solution, have certain adhesive effect is about 50 μ m needs the binding agent that is suitable for fine powder or other pharmacy; Described fine polymer powder is selected from PVP
K30Fine powder, PVP
K15Fine powder, Macrogol 4000 fine powder or polyethylene glycol 6000 fine powder; When adopting lyophilization to prepare tablet, described binding agent is selected from PVP fine powder, water-soluble solid Polyethylene Glycol, gelatin, xanthan gum, pectin, Resina persicae, arabic gum, guar gum or alginate.
Described disintegrating agent is selected from the disintegrating agent that cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium or other pharmacy with powerful disintegrating property are suitable for.
Other adjuvants that described pharmacy is suitable for comprise antiseptic, surfactant and lubricant.
The preparation method of vagina fast-release tablet of the present invention can adopt direct compression process, and the technology of utilizing general sheeting equipment to prepare the vagina fast-release tablet comprises:
Step 1. crushing screening: active constituents of medicine and adjuvant pulverize separately sieve, and make the fine powder of the about 50 μ m of particle diameter.
Step 2. is mixed: take by weighing the principal agent fine powder and the adjuvant fine powder of 1 preparation set by step by recipe quantity, with 2/3 disintegrating agent wherein and all the lubricant fine powders give over to standby, then with principal agent fine powder and all the other adjuvant fine powder mix homogeneously.
3. granulate: add binder solution in the main materials and auxiliary materials fine powder behind mixing and stir, cross the 14-20 eye mesh screen and make wet grain, and under 60 ℃ of temperature, dry.
4. add and add adjuvant and granulate: add the granule after oven dry outside and add adjuvant: promptly give over to standby 2/3 disintegrating agent and whole lubricant fine powder fine powders, with 20 mesh sieve granulate, mix homogeneously behind the granulate.
5. tabletting: will sending into general tablet machine through the granule behind the granulate, to make hardness be 1.5-2.5kg/cm
2Tablet.
Adopt the vagina fast-release tablet of method for preparing to compare with general tablet, preparation equipment is identical, but preparation technology's feature difference.Be the disintegrate rapidly under the lower situation of hardness of assurance tablet, and have suitable mechanical strength, wearability and good appearance; One, pressure is 1.0-8.0kg/cm less than conventional sheet but its pressure should guarantee tablet hardness during tabletting
2, preferred tablet hardness is 1.5-2.5kg/cm
2Two, except that the strong disintegrating agent of preferred disintegrating property, add mode and outer add mode two parts in its adding mode is divided into promptly are added in the granule in above-mentioned steps 3, disintegrating agent and lubricant are together added tabletting again behind the mixing in above-mentioned steps 4.
Adopt the vagina fast-release tablet of method for preparing, outward appearance is compared with general tablet, and the surface is more smooth smooth, mechanical strength and wearability tool are good, in the test of intravaginal and hanging basket method, have that good speed collapses, instant capacity, tablet is put into vagina, is disintegratable in 60 seconds.
The preparation method of vagina fast-release tablet of the present invention can adopt the lyophilizing method of tableting, and preparation technology comprises:
Step 1. dosing: active constituents of medicine and adjuvant pulverize separately are sieved, be prepared into the fine powder of particle diameter, will obtain binder solution in the water-soluble or rare alcohol of the binding agent of recipe quantity less than 50 μ m; The soluble agents active component and the filler of recipe quantity are dissolved in the above-mentioned binder solution, add insoluble drugs active component and surfactant then and stir into suspension, add the surfactant that pharmacy is suitable for again, obtain stable drug suspension.
Step 2. minute vehicle is to mould: the above-mentioned drug suspension for preparing is dispensed in " polynary depression model ", liquid amount should be full of the depression model just but be not excessive.
Step 3. lyophilizing: adopt the freezing equipment of preparation injection lyophilized preparation to carry out pre-freeze, distillation and drying.
Pre-freeze: the polynary depression model that will distribute medicinal liquid is inserted in the freeze dryer drying baker, and it is freezing to lower the temperature, and makes medicinal liquid freeze, freeze reality in the depression model, and the pre-freeze temperature remains on-40 ℃--in 60 ℃ of scopes.
Distillation: medicinal liquid freeze and freeze real after, open the freeze dryer vacuum pump, make the vacuum in the freeze dryer reduce to 30 millibars, kept 60-120 minute, make the water sublimed in the lyophilizing tablet.
Dry: as after sublimation process finishes, to make the temperature in the freeze dryer rise to 20-30 ℃, kept 120-180 minute.
Step 4. capping: will from freeze dryer, take out through the dried polynary depression mould plate that contains tablet, and be hot-pressed onto with aluminium plastic membrane immediately and contain tablet mould plate upper cover, and, get product in order to avoid absorb moisture.
Adopting the vagina fast-release tablet of above-mentioned lyophilization preparation is the hemispherical sheet of porous grid structure, the quality comparatively dense, and the surface is level and smooth inadequately, but suitable mechanical strength is arranged, and is difficult for fragmentation when packing is taken, and it is faster in intravaginal collapsing property of speed, instant capacity is better.
Adopt above-mentioned lyophilization to prepare the vagina fast-release tablet, preparation technology's key is for must prepare a kind of powder charge liquid mould in advance, contain " polynary depression model " on Die and mould plate, its shape can be the depression model of " hemisphere depression " or other shapes, and its volume size is determined by the powder charge liquid measure.Amount of liquid medicine must be full of just and can not overflow, and guarantees the accurate of dose.The PVC thin web that the preferred pharmacy of material of the depression model of preparation is suitable for.Made " polynary depression model " very such tablets and capsule blister package removes shape behind tablet or the capsule.
Adopt the vagina fast-release tablet of above-mentioned direct compression process and lyophilization preparation to have all that stronger speed collapses, instant capacity.According to " Chinese Pharmacopoeia version in 2000 ", disintegration of tablet time limit determinator and method (hanging basket method) adopt above-mentioned direct compression process to prepare vagina speed disintegrating tablet, and its disintegration is less than 60 seconds, generally disintegrate or dissolving rapidly in 30 seconds; It is shorter disintegration to adopt above-mentioned lyophilization to prepare vagina speed disintegrating tablet, disintegratable or dissolving in 45 seconds, generally disintegrate or dissolving rapidly in 20 seconds.
Experiment in the vagina fast-release tablet animal body: with the female sheep of adult healthy is experimental animal.Vagina fast-release tablet of the present invention is pushed its intravaginal 2-3cm with finger from vaginal orifice, and the process short time detects whether have not disintegrate or solution tablet again.The vagina fast-release tablet of general pressed disc method preparation about 1 minute promptly disintegrate disperse or dissolve, and the vagina fast-release tablet of lyophilization preparation less than time of 45 seconds promptly disintegrate disperse or dissolve.The contrast tablet is general oral, and in the same animals intravaginal, 5 minutes still can not disintegrate.
The usage of vagina fast-release tablet of the present invention: get the vagina fast-release tablet and place vaginal orifice, push the vagina appropriate depth lightly with the finger of putting on medical gloves and get final product, easy to use, do not need appurtenance, patient oneself also can operate.In addition, it should be noted that the meaning of " rapid release " of the present invention is meant rapidly " disintegrate dispersion " or " dissolving ", medicine is dispersed in vaginal mucosa rapidly, is beneficial to absorption.
It is worthy of note that vagina fast-release tablet of the present invention not only is suitable for vagina administration, also can be used for drop rectum with drug.
The invention has the beneficial effects as follows: the vagina fast-release tablet is inserted intravaginal, and the contact vaginal secretions can disperse or dissolve in rapid disintegrate, the medicine transvaginal mucosa absorption of release, and the performance local therapeutic effects, or enter the body circulation, the effect of performance whole body therapeutic.It is convenient to use, and does not need special appurtenance, rare sense of discomfort, and medicine does not overflow outside the vagina, and medication is accurate, good patient compliance.Simple and practical, the low cost of manufacture of preparation method.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is described in further detail:
Embodiment 1
Misoprostol vagina fast-release tablet, the weight of each component is in its per 1000:
Misoprostol dispersion 2.5g (converting pure misoprostol 25mg)
Mannitol 94g
Microcrystalline Cellulose 40g
Cross-linking sodium carboxymethyl cellulose 6g
PVP
K30 4g
Magnesium stearate 4g
The preparation method of misoprostol vagina fast-release tablet is:
Step 1. crushing screening: said medicine and adjuvant pulverize separately are sieved, about fine powder particle diameter 50 μ m.
Step 2. is mixed: take by weighing misoprostol dispersion and pharmaceutic adjuvant fine powder by recipe quantity, with 2/3 disintegrating agent wherein and all the lubricant fine powders give over to standby, then with principal agent fine powder and all the other adjuvant fine powder mix homogeneously.
Step 3. is granulated: with 7.5%PVP
K30Aqueous solution or 70% alcoholic solution are made soft material in right amount and are crossed the granulation of 18 mesh sieves, and wet grain must be done granule in 60 ℃ of dryings.
Step 4. adds and to add adjuvant and granulate: add the granule after oven dry outside and add adjuvant: promptly give over to standby 2/3 disintegrating agent and whole lubricant fine powder fine powders, with 20 mesh sieve granulate, mix homogeneously behind the granulate.
Step 5. tabletting: adopt general tablet machine tabletting, regulate the pressure of tabletting, the control tablet hardness.
Sheet is heavy: 150mg slice, thin piece hardness: 1.8kg/cm
2
Disintegration time mensuration: press Chinese Pharmacopoeia version in 2000, bracketplant is improved one's methods, and surveys disintegration, disintegrate in 45 seconds; Experiment in the animal body: disintegrate in 60 seconds.
Embodiment 2
Levofloxacin vagina fast-release tablet, the weight of each component is in its per 1000:
Levofloxacin 100g
Mannitol 39g
Gelatin 10g
PEG6000 6g
The preparation method of levofloxacin vagina fast-release tablet comprises:
Step 1. dosing:, get particle diameter 50 μ m fine powders with the levofloxacin crushing screening.Get the 700ml pure water, add the recipe quantity gelatin, be heated to 60 ℃ of stirring and dissolving, add mannitol and PEG6000 and make dissolving, cool to room temperature.Add the levofloxacin fine powder then, stir into suspension, add pure water to 750ml.As essential, then add suitable pharmacy appropriate table surface-active agent, make into stable suspension.
Step 2. medicinal liquid distributes: above-mentioned medicinal liquid is rationed to the many units of PVC depression model, and each depression model 0.75ml.
Step 3. lyophilizing: the PVC model that will contain medicinal liquid is pulled and is inserted in the freeze dryer, finishes freeze-drying process through pre-freeze, distillation, drying.Lyophilization cycle 2.5-3.0 hour.
Step 4. capping: the freeze dried mould plate that contains tablet is taken out, use the aluminum-plastic composite membrane capping immediately.
Usage: the time spent is opened the aluminum plastic film that depression covers, and releases the semi-spherical shape tablet from depression model bottom, pushes vagina lightly with finger and gets final product.
Sheet is heavy: 155mg slice, thin piece hardness: 2kg/cm
2
Disintegration time mensuration: press Chinese Pharmacopoeia version in 2000, hanging basket is improved one's methods, and surveys disintegration, disintegrate in 30 seconds; Experiment in the animal body: disintegrate in 45 seconds.
Embodiment 3
Azithromycin vagina fast-release tablet, the weight of each component is in its per 1000:
Azithromycin 25g
Lactose 30g
Microcrystalline Cellulose 15g
Polyvinylpolypyrrolidone 4.5g
PVP
K30 3g
Magnesium stearate 3g
The preparation method of azithromycin vagina fast-release tablet is with embodiment 1.
The heavy 800mg hardness of sheet 2.0kg/cm
2
Disintegration time mensuration: press Chinese Pharmacopoeia version in 2000, bracketplant is improved one's methods, and surveys disintegration, disintegrate in 45 seconds; Experiment in the animal body: disintegrate in 60 seconds.
Claims (9)
1. a vagina fast-release tablet comprises: the adjuvant that active constituents of medicine and pharmacy are suitable for; Described active constituents of medicine comprises: antibiotics, antimycotic, antiviral class, hormones, prostaglandins, family planning class, hemostasis class, antipyretic analgesic class, anti-dysmenorrhea class or other are applicable to the active constituents of medicine of intravaginal medication; The adjuvant that described pharmacy is suitable for comprises: filler, binding agent and disintegrating agent; It is characterized in that: described filler comprises water-soluble filler and water-insoluble filler, and the two weight ratio is 10: 0.5-0.5: 10, and the two total consumption is the heavy 15-75% of sheet; When adopting direct compression process to prepare tablet, described adhesive consumption is the heavy 0.5-20% of sheet, and when adopting lyophilization to prepare tablet, described adhesive consumption is the heavy 1.0-40% of sheet; Described disintegrating agent is selected from the disintegrating agent that cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium or other pharmacy with powerful disintegrating property are suitable for, and its consumption is the heavy 0.5-20% of sheet.
2. vagina fast-release tablet according to claim 1 is characterized in that: described water-soluble filler is selected from sucrose, lactose, glucose, maltose or other water-soluble sugars, mannitol, sorbitol, xylitol, erithritol or other water solublity sugar alcohols, glycine, lysine, proline or other water-soluble amino acid, taurine; Described water-insoluble filler comprises: starch based and cellulose family filler; Described starch based is selected from the starch that starch, pregelatinized Starch or other pharmacy are suitable for; Described cellulose family is selected from the filler that the suitable water-insoluble of microcrystalline Cellulose, ethyl cellulose, low-substituted hydroxypropyl cellulose or other pharmacy has disintegrating property concurrently.
3. vagina fast-release tablet according to claim 1 and 2, it is characterized in that: the fine polymer powder that the particle diameter that when adopting direct compression process to prepare tablet, described binding agent is selected from syrup, gelatinized corn starch, CMC-Na solution, PVP solution, have certain adhesive effect is about 50 μ m needs the binding agent that is suitable for fine powder or other pharmacy; Described fine polymer powder is selected from PVP
K30Fine powder, PVP
K15Fine powder, Macrogol 4000 fine powder or polyethylene glycol 6000 fine powder; When adopting lyophilization to prepare tablet, described binding agent is selected from PVP fine powder, water-soluble solid Polyethylene Glycol, gelatin, xanthan gum, pectin, Resina persicae, arabic gum, guar gum or alginate.
4. vagina fast-release tablet according to claim 1 and 2 is characterized in that: other adjuvants that described pharmacy is suitable for comprise antiseptic, surfactant and lubricant.
5. according to the direct compression process preparation method of the described vagina fast-release tablet of claim 1, comprising: step 1: crushing screening; Step 2: mix; Step 3: granulate; Step 4: adding adds adjuvant and granulate; Step 5: tabletting; It is characterized in that:
Described step 2 is: take by weighing set by step the principal agent fine powder and the adjuvant fine powder of 1 preparation by recipe quantity, with 2/3 disintegrating agent wherein and all the lubricant fine powders give over to standby, then with principal agent fine powder and all the other adjuvant fine powder mix homogeneously;
Described step 4 is: add outside the granule after oven dry and add adjuvant: promptly give over to standby 2/3 disintegrating agent and whole lubricant fine powders, with 20 mesh sieve granulate, mix homogeneously behind the granulate;
To make hardness be 1.5-2.5kg/cm to described step 5 in order sending into general tablet machine through the granule behind the granulate
2Tablet.
6. according to the lyophilization preparation method of the described vagina fast-release tablet of claim 1, comprising: step 1. dosing, step 2. minute vehicle to mould, step 3. lyophilizing and step 4. capping; It is characterized in that: described step 3 comprises: pre-freeze, distillation and dry three phases: pre-freeze: the polynary depression model that will distribute medicinal liquid is inserted in the freeze dryer drying baker, it is freezing to lower the temperature, make medicinal liquid freeze, freeze reality in the depression model, the pre-freeze temperature remains on-40 ℃--in 60 ℃ of scopes; Distillation: medicinal liquid freeze and freeze real after, open the freeze dryer vacuum pump, make the vacuum in the freeze dryer reduce to 30 millibars, kept 60-120 minute, make the water sublimed in the lyophilizing tablet; Dry: as after sublimation process finishes, to make the temperature in the freeze dryer rise to 20-30 ℃, kept 120-180 minute.
7. according to aforesaid right 1 described vagina fast-release tablet, it is characterized in that: be misoprostol vagina fast-release tablet, the weight of each component is in its per 1000:
Misoprostol dispersion 2.5g
Mannitol 94g
Microcrystalline Cellulose 40g
Cross-linking sodium carboxymethyl cellulose 6g
PVP
K30 4g
Magnesium stearate 4g
8. according to aforesaid right 1 described vagina fast-release tablet, it is characterized in that: be levofloxacin vagina fast-release tablet, the weight of each component is in its per 1000:
Levofloxacin 100g
Mannitol 39g
Gelatin 10g
PEG6000 6g
9. according to aforesaid right 1 described vagina fast-release tablet, it is characterized in that: be azithromycin vagina fast-release tablet, the weight of each component is in its per 1000:
Azithromycin 25g
Lactose 30g
Microcrystalline Cellulose 15g
Polyvinylpolypyrrolidone 4.5g
PVP
K30 3g
Magnesium stearate 3g
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03130267 CN1214784C (en) | 2003-06-27 | 2003-06-27 | Quick-releasing talbet in vagina and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03130267 CN1214784C (en) | 2003-06-27 | 2003-06-27 | Quick-releasing talbet in vagina and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1473561A CN1473561A (en) | 2004-02-11 |
| CN1214784C true CN1214784C (en) | 2005-08-17 |
Family
ID=34153695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03130267 Expired - Lifetime CN1214784C (en) | 2003-06-27 | 2003-06-27 | Quick-releasing talbet in vagina and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1214784C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1958007B (en) * | 2005-10-31 | 2010-09-08 | 哈尔滨儿童制药厂 | Vagina tablet for treating cervicitis, cervical erosion, and preparation method |
| CN102048759A (en) * | 2009-11-03 | 2011-05-11 | 深圳市嘉轩医药科技发展有限公司 | Gamuzhuer vagina tablet and preparation method thereof |
| CN102697746B (en) * | 2012-06-11 | 2014-03-19 | 广州朗圣药业有限公司 | Rapid melting misoprostol vaginal composition as well as preparation method and application of same |
| CN102784120B (en) * | 2012-08-23 | 2014-03-26 | 海南卫康制药(潜山)有限公司 | Metronidazole composition freeze-dried disintegrating tablets for vaginas and preparation method thereof |
| CN104510718A (en) * | 2013-09-27 | 2015-04-15 | 天津孚音生物科技发展有限公司 | Misoprostol solid composition capable of being stored at room temperature and used for vagina, and preparation method thereof |
| CN104922235B (en) * | 2015-05-15 | 2018-05-04 | 浙江中医药大学 | A kind of coptis chinensis total alkaloid vaginal gel |
| CN105381452A (en) * | 2015-11-16 | 2016-03-09 | 游莲莲 | Pharmaceutical composition for treating hypertrophy of uterus caused by blood heat and preparation method of pharmaceutical composition |
| CN108434110B (en) * | 2018-04-28 | 2019-09-10 | 浙江仙琚制药股份有限公司 | Misoprostol composition, tablet and application thereof |
-
2003
- 2003-06-27 CN CN 03130267 patent/CN1214784C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1473561A (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278932B (en) | Sustained release medicinal compositions containing Zaltoprofen, preparation method and application thereof | |
| CN1281356A (en) | Quickly soluble solid preparations | |
| WO1995020380A1 (en) | Intraorally soluble compressed molding and process for producing the same | |
| CN1911211A (en) | Solid oral prepn. of leishajilan | |
| WO2013123623A1 (en) | Oroally disintegrating tablet and preparation method therefor | |
| JP3064417B2 (en) | Controlled release formulations and methods | |
| CN1214784C (en) | Quick-releasing talbet in vagina and its preparing method | |
| CN101695491A (en) | Slow-release preparation of repaglinide | |
| JP6479658B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN102204980A (en) | Wuji (liver-fire-purging and spleen-stomach-regulating) gastric stasis preparation and preparation method thereof | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN1927342A (en) | Heat clearing and detoxicating dispersant tablet and method for making same | |
| WO2017038455A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| CN1781479B (en) | Chinese small iris seed agent dispersion system and its preparing method | |
| CN1709243A (en) | Vagina medicine containing ebselen and its use | |
| CN100536829C (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| CN102028665A (en) | Nimodipine oral fast dissolving tablets and preparation method thereof | |
| CN101305988A (en) | Compound alendronate sodium vitamine D3 orally disintegrating tablets and preparation method thereof | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN102188405A (en) | New cavity administration preparation formulation | |
| CN103191048B (en) | A kind of preparation method of oleanolic acid bioadhesive preparation | |
| CN1634073A (en) | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN LONG BAI BIOLOGICAL ENGINEERING TECHNOLOGY Free format text: FORMER OWNER: LIU HUI Effective date: 20090619 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090619 Address after: Tianjin New Technology Industrial Park Huayuan Industrial District Guangdong Road No. 6 Building No. 2 1 601 Patentee after: LONGBAI BIOENGINEERING SCIENCE Address before: 16-56-102, Longhai apartment, Jiefang South Road, Tianjin, Hexi District Patentee before: Liu Hui |
|
| ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN BOTAI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LONGBAI BIOENGINEERING SCIENCE AND TECHNOLOGY CO LTD, TIANJIN CITY Effective date: 20130216 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300384 NANKAI, TIANJIN TO: 130012 CHANGCHUN, JILIN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130216 Address after: 130012 No. 1050, Optics Valley Avenue, Changchun hi tech Zone, Jilin Patentee after: CHANGCHUN BOTAI MEDICINE AND BIOLOGICAL TECHNOLOGY CO.,LTD. Address before: 300384 Zhu Yuan Tianjin New Technology Industrial Park Huayuan Industrial District Road No. 6 Building No. 2 1 601 Patentee before: LONGBAI BIOENGINEERING SCIENCE |
|
| ASS | Succession or assignment of patent right |
Owner name: NINGBO LIWAH PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHANGCHUN BOTAI BIOTECHNOLOGY CO., LTD. Effective date: 20140102 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130012 CHANGCHUN, JILIN PROVINCE TO: 315174 NINGBO, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140102 Address after: Yinzhou District Gaoqiao Town new village 315174 Zhejiang city of Ningbo Province Patentee after: NINGBO LIWAH PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 1050, Optics Valley Avenue, Changchun hi tech Zone, Jilin Patentee before: CHANGCHUN BOTAI MEDICINE AND BIOLOGICAL TECHNOLOGY CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050817 |
|
| CX01 | Expiry of patent term |